Antech, a subsidiary of Mars Science and Diagnostics, has launched a new, rapid canine cancer test for use in practice, in the UK and Europe.

The Nu.Q Canine Cancer Test is a new technology that measures circulating nucleosomes in order to enable earlier cancer detection in some of the most common types of canine cancers.

According to the company, Nu.Q testing requires only 50µL of EDTA plasma from a patient and provides accurate results in 5 to 10 minutes.

One study demonstrated >75% detection rates for common cancers in dogs like lymphoma and hemangiosarcoma when using Nu.Q1.

The company suggests veterinary professionals use the tool during annual check-ups or regular senior wellness exams for older dogs and at-risk breeds.

Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech, said: “It’s exciting to see innovations like Nu.Q Canine Cancer Test become more widely available to veterinary teams in Europe.

"With cancer affecting one in four dogs2, it is critical that veterinary professionals have access to fast and accurate cancer screening methods, so they can make informed and timely decisions and ultimately change pet health outcomes. 

https://antechdiagnostics.co.uk 

References

  1. https://www.avma.org/resources/pet-owners/petcare/cancer-pets#:~:text=Approximately%201%20in%204%20dogs,rate%20of%20cancer%20in%20cats.
  2. Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res 18, 329 (2022). https://doi.org/10.1186/s12917-022-03429-8 

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.